Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
30/09/2026 11:15
BRIEF-Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30 Sept 30 (Reuters) - Sagimet Biosciences Inc. SGMT.O:
SAGIMET BIOSCIENCES - SUSPENDS AND TERMINATES ATM PROSPECTUS SUPPLEMENT FOR SERIES A COMMON STOCK EFFECTIVE SEPT 30 - SEC FILING
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage